☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
ADC Therapeutics
ADC Therapeutics Announces the Results of Zynlonta in the P-II Trial for the Treatment of Follicular Lymphoma
December 13, 2023
ADC Therapeutics Voluntary Pauses Patients Enrolment in the P-II Study (LOTIS-9) of Zynlonta and Rituximab for Diffuse Large B-Cel...
July 12, 2023
Insights+: The US FDA New Drug Approvals in April 2021
May 13, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.